Comparison of Mucin Levels at the Ocular Surface of Visual Display Users With and Without Dry Eye Disease

NCT05604651 | Completed

• 1 other identifier: VDT
• Study Type: observational
• Target: 94
• Locations: 1 country
• Sites: 1

Brief Summary

The study aimed to evaluate 1) if levels of the glycocalyx membrane mucins, including MUC1, MUC4, MUC16 and MUC20, are altered in conjunctival cells of visual display users With and Without Dry Eye Disease, and 2) if mucin levels correlate with dry eye clinical diagnostic data.

Conditions

Dry Eye Disease

Keywords

Dry Eye Disease; Mucin

Outcome Measures

Primary Outcomes (1)

• mucin expression

  The mRNA expression of mucin was measured by Quantitative real-time PCR, which is a laboratory technique of molecular biology to find out how much of a specific section of DNA there is in a sample.

  immediately after meeting the inclusion and exclusion criteria

Study Arms (2)

dry eye disease

Dry eye disease was diagnosed according to the Tear Film and Ocular Surface Society (TFOS) DEWS II criteria: (1) Ocular Surface Disease Index (OSDI) score ≥ 13 and (2) one of these signs; fluorescein tear breakup time (TBUT) \<10 sec; abnormal ocular surface staining (\>5 corneal spots or \> 9 conjunctival spots).

Other: no intervention

control

The controll group enrolled healthy participants without ocular and systemic diseases.

Other: no intervention

Interventions

no intervention OTHER

no intervention

control; dry eye disease

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Video display terminals users with and without dry eye disease.

You may qualify if:

• Participants who exposed to video display terminals for more than 1 year (at least 5 days per week and 6 hours per day) were enrolled and divided into two groups: (1) VDT users with DED and (2) VDT users without DED. DED was diagnosed according to the Tear Film and Ocular Surface Society (TFOS) DEWS II criteria: (1) Ocular Surface Disease Index (OSDI) score ≥ 13 and (2) one of these signs; fluorescein tear breakup time (TBUT) \<10 sec; abnormal ocular surface staining (\>5 corneal spots or \> 9 conjunctival spots).

You may not qualify if:

• a history of contact lens wear or ocular surgery within 2 year of the study visit; a history of previous ocular disease; topical or systemic therapies other than artificial tears within two weeks before recruitment; and inflammatory ocular diseases, ocular surface diseases, glaucoma and systemic diseases with ocular involvement, such as meibomian gland dysfunction, diabetes, and peripheral neuropathy.

Sponsors & Collaborators

• Peking University Third Hospital: lead

Study Sites (1)

Peking University Third Hospital

Beijing, 100191, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Conjunctival impression cytology samples

MeSH Terms

Conditions

Dry Eye Syndromes; Medullary cystic kidney disease 1

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases

Study Officials

• Hong Qi, PhD

  Peking University Third Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 29, 2022
• First Posted: November 3, 2022
• Study Start: March 1, 2021
• Primary Completion: September 2, 2021
• Study Completion: September 2, 2021
• Last Updated: November 23, 2022

Record last verified: 2022-10

Locations

CN (1)